Clinical Context
Pediatric type 1 diabetes management is notoriously difficult, with most children and adolescents failing to achieve glycemic targets. Mean HbA1c levels in pediatric populations typically exceed 8%, well above the <7% target recommended for adults and the <7.5% target suggested for youth. The challenges are multifactorial: developmental changes in insulin sensitivity, unpredictable eating and activity patterns, psychological factors including diabetes distress and burnout, and the inherent complexity of replicating physiological insulin secretion with exogenous injections.
Continuous glucose monitoring (CGM) has transformed diabetes care by providing real-time glucose data and trend information. However, CGM alone doesn’t improve outcomes—it’s what patients and families do with the data that matters. Many families feel overwhelmed by the constant data stream, uncertain how to interpret patterns, or unable to translate insights into actionable changes. The potential of CGM is often unrealized without adequate support and education.
Telehealth offers a mechanism to provide frequent, data-driven support that would be impractical with traditional in-person visits. Remote CGM data sharing allows clinicians to review glucose patterns between appointments and provide timely, personalized guidance. This study evaluated whether intensive weekly telehealth support could translate CGM data into improved glycemic outcomes in children and adolescents using multiple daily injections (MDI).
PICO Summary
Population: Children and adolescents with type 1 diabetes using FreeStyle Libre 2 continuous glucose monitoring (CGM) and multiple daily insulin injections (MDI), with suboptimal glycemic control.
Intervention: Intensive, integrated telehealth intervention with weekly remote monitoring sessions and personalized feedback over 12 weeks, including CGM data review, insulin dose adjustment guidance, and lifestyle counseling.
Comparison: Standard diabetes care with routine clinic follow-up (typically quarterly visits) without intensive telehealth support, in a crossover design allowing each participant to serve as their own control.
Outcome: The telehealth intervention significantly improved glycemic control: HbA1c decreased by approximately 0.3% compared to the control period, and time-in-range (70-180 mg/dL) increased meaningfully. The intervention was well-tolerated with no increase in hypoglycemia. Caregiver engagement was required but acceptable to most families.
Clinical Pearls
1. Frequency Matters: Weekly contact—far more frequent than typical quarterly clinic visits—enabled iterative dose adjustments and timely problem-solving. This mirrors how diabetes educators have long known that intensive early support produces better outcomes, but resource constraints typically preclude such frequent contact.
2. CGM Enables Data-Driven Telehealth: The combination of CGM and telehealth creates a powerful synergy. CGM provides objective data that can be reviewed remotely, while telehealth provides the interpretation and guidance that transforms data into action. Neither alone achieves what both together accomplish.
3. Safety Was Maintained: Intensive insulin adjustment guidance didn’t increase hypoglycemia, addressing a common concern about remote dose management. The real-time nature of CGM data allows safer adjustment than relying solely on fingerstick glucose values or HbA1c.
4. Crossover Design Strengthens Conclusions: Having each participant serve as their own control eliminates between-subject variability—the improvement observed is attributable to the intervention rather than differences between intervention and control groups.
Practical Application
For pediatric diabetes programs, this study supports investment in telehealth infrastructure to enable frequent remote CGM review and patient contact. The weekly session model, while resource-intensive, produced meaningful glycemic improvements that would be difficult to achieve with traditional care models.
Implementation considerations include ensuring families have data-sharing capabilities (most CGM systems now support cloud-based sharing), developing protocols for remote data review and dose adjustment, training staff in telehealth delivery, and setting realistic expectations about engagement demands. Not all families will sustain weekly contact long-term; the intervention may be most valuable as an intensive initiation phase followed by maintenance support.
Target patients who might benefit most: newly diagnosed patients establishing management routines, patients with deteriorating control who need intensive re-engagement, patients transitioning between insulin regimens, and motivated families seeking optimization but lacking access to frequent in-person visits.
Broader Evidence Context
This study adds to growing evidence supporting telehealth in diabetes care, which accelerated during the COVID-19 pandemic but has been sustained by demonstrated effectiveness and patient preference. Multiple studies have shown telehealth can maintain or improve glycemic outcomes compared to in-person care alone, with advantages in access and convenience.
The pediatric-specific evidence is particularly important given the unique challenges of managing type 1 diabetes in children and adolescents. The engagement of caregivers alongside patients reflects the family-centered nature of pediatric diabetes management.
Study Limitations
The 12-week intervention duration demonstrates short-term efficacy but doesn’t address sustainability of benefits or optimal long-term telehealth frequency. Resource requirements for weekly sessions may limit scalability. Selection bias may have enrolled more motivated families. The MDI-specific population may not generalize to insulin pump users.
Bottom Line
Intensive weekly telehealth support significantly improves glycemic control (HbA1c reduction ~0.3%, increased time-in-range) in children and adolescents with type 1 diabetes using CGM and multiple daily injections. The intervention safely enhanced glycemic outcomes through data-driven, frequent contact that traditional care models cannot provide. Telehealth-enabled CGM review represents a promising approach to closing the gap between actual and target glycemic control in pediatric type 1 diabetes.
Source: Deeb A, et al. “Effect of an Intensive, Integrated Telehealth Intervention on Glycemic Control in Children and Adolescents With Type 1 Diabetes Using Continuous Glucose Monitoring: A Randomized, Crossover Trial.” Read article
